Comparative Evaluation of Standardization, Application and Awareness of Panax Ginseng and Ashwagandha Based Medical Products: India's Context

Panax ginseng together with Ashwagandha (Withania somnifera) are the most important adaptogens of the Indian herbal market which is expected to be worth USD 2.16 billion by 2033. In the present situation, these two herbal plants are undergoing standardization within the frameworks of FSSAI and AYUSH, are being studied for their therapeutic uses in nutraceuticals and Ayurveda, and are being assessed for consumer awareness against regulatory and market dynamics. The standardization of Ashwagandha is being supported through national pharmacopoeias as well as withanolide indicators, while that of Panax ginseng relies on import-based ginsenoside characterization with global inconsistencies. Among the therapeutic uses, both plants are found to be stressed-relievers and immune-boosters, although Ashwagandha has more clinical studies in the local scenario supporting its use. Awareness adds a favorable point for Ashwagandha due to its cultural incorporation, in contrast to ginseng's more limited status. The findings encourage the establishment of common standards and training to facilitate the integration of ginseng.